Companies›Healthcare›Healthcare›Healthcare Services
NSE:KRSNAA

KRSNAA DIAGNOSTICS LTD

Healthcare › Healthcare Services
₹496.00
at close · 27 Oct 2026
▼ 1.50 (-0.30%)

Latest filings

Next results: Mon, 2 Nov · Financial Results
  1. Krsnaa Diagnostics schedules Q2 and H1 FY27 earnings call · Board & Shareholder Meetings
  2. Board meeting set for November 2 to approve quarterly results · Results
  3. Krsnaa Diagnostics collaborates with AZmed on artificial intelligence radiology · Strategic Transactions
All filings ↓
Ask Nexa about KRSNAA DIAGNOSTICS LTD

Snapshot

What the business is, and whether it's a good one at a fair price.

AI · written from filings

Runs a nationwide diagnostic services network under public-private partnership (PPP) contracts with state governments, alongside a growing retail diagnostics brand. Operates 190+ CT/MRI centers, 147 pathology labs and 4,700+ patient collection centers across 18 states, processing 59 million tests and serving 20 million patients in FY26. The PPP arm — including a Rajasthan project with 27 mother labs and 800+ collection centers, and a new 7-year Himachal Pradesh contract covering CT scans at 34 government health institutions — supplies the bulk of revenue, with FY27 capex of ₹500 crore earmarked for further expansion (₹300+ crore Rajasthan, ₹150+ crore MRI). The retail arm operates 3,500+ touchpoints across 5 states with 54 NABL-accredited labs and 54 NABH-accredited radiology centers, contributing ~8% of FY26 revenue at ~₹60 crore. Costs split as materials (23.2% of revenue), employees (18.2%), other opex (31.2%) and depreciation (11.7%); FY26 capex ran at 28.4% of revenue. Days sales outstanding stood at 139 days at year-end versus 155 days earlier, with a sub-120 day FY27 target.

Operating scale
CT/MRI centers
190+ across 18 statesFY26
Pathology labs
147FY26
Patient collection centers
4,700+FY26
Tests processed
59 millionFY26
Patients served
20 millionFY26
Retail touchpoints
3,500+ across 5 statesFY26
Who pays it
State governments via PPP contracts (Rajasthan, Himachal Pradesh, others) and walk-in patients at retail centers.
Biggest cost
Materials and reagents for diagnostic testing at 23.2% of revenue; employee costs the next-largest line at 18.2%.
Kind of business
Asset-heavy diagnostic infrastructure (FY26 capex 28.4% of revenue) with government-counterparty-heavy receivables and long collection cycles (DSO 139 days).
Where it sits
Multi-state diagnostic PPP operator present across 18 states; ICRA A/Stable long-term rating reaffirmed on ₹166.60 crore of bank facilities and ICRA A1 on ₹137.55 crore of bank guarantees (₹304.15 crore total rated).
Market Cap
₹1,609 Cr
P / E (TTM)
16.5×
EV / EBITDA
8.0×
Div Yield
0.55%
Growth
—·
Revenue 5y CAGR
PAT — · EBITDA —
Quality
10.8%·
ROCE (5y median)
ROE 8.8% (5y median) · margin 33.0%
Leverage
0.55·
Debt / Equity · moderate
Net debt ₹504 Cr
Revenue FY22→FY26
1.7×▲
Margin −1.9 pts
₹455 Cr → ₹773 Cr
Cash conversion
1.25×▲
Operating cash ÷ profit · 5 yrs
₹459 Cr on ₹366 Cr
Moves on a normal day
1.19%·
Median daily move
Last 267 sessions · the yardstick for filing-day moves
Where it sits among 29 Healthcare Service Provider peersBar = share of peers beaten · tick = industry median · latest reported figures
P/E (TTM)#8/25
P/B#11/24
ROCE#12/29
ROE#9/24
Debt / Equity#19/23
EBITDA margin#11/24
Revenue growth#11/25
Profit growth#19/25

Scorecard

Measured from the filed financials, judged against its Healthcare Service Provider peers · as of FY26 — not investment advice

Strengths
Over 5 years it reported ₹366 Cr of profit and ₹459 Cr of operating cash — 1.25×
Profit is converting into cash
Concerns
Carries more debt than its peers — 0.55× equity
higher than 82% of its 23 Healthcare Service Provider peers
Heavy working capital — 122 days of cash tied up
Customers are taking longer to pay — 46 → 140 days of receivables
FY22 → FY26

Charts

How has the market priced it — with filings on the timeline?

KRSNAA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Peers

How does it stack up on valuation, returns and growth?

Loading peers…

Financials

Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.

Loading financials…

Ownership

Who owns it — and is the promoter stake clean?

Loading shareholding…

Sign up to see the full company file

Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.

Common questions

Answered from KRSNAA DIAGNOSTICS LTD's filed financials and exchange disclosures

What does KRSNAA DIAGNOSTICS LTD do?

KRSNAA DIAGNOSTICS LTD is a Healthcare Services company listed on NSE and BSE, trading under the symbol KRSNAA.

Is KRSNAA DIAGNOSTICS LTD profitable?

Yes. Over the trailing twelve months KRSNAA DIAGNOSTICS LTD reported a net profit of ₹97 Cr on revenue of ₹815 Cr.

Does KRSNAA DIAGNOSTICS LTD pay a dividend?

Yes. The dividend yield is 0.55% at the current price. It paid out 9% of its profit as dividend in FY26.

Is KRSNAA DIAGNOSTICS LTD debt-free?

No. It reported borrowings of ₹534 Cr on its 31 Mar 2026 balance sheet, or net debt of ₹504 Cr after cash. Debt stands at 0.55× equity. That is higher than 82% of its 23 Healthcare Service Provider peers.

Is KRSNAA DIAGNOSTICS LTD expensive compared with its peers?

On trailing P/E, KRSNAA DIAGNOSTICS LTD ranks 8 of 25 in Healthcare Service Provider — cheaper than 71% of them, against an industry median of 23.6×. This is a position, not a valuation judgement.

How much does the KRSNAA DIAGNOSTICS LTD share price move in a day?

On a typical session KRSNAA DIAGNOSTICS LTD moves 1.19% — that is the median absolute close-to-close move across its last 267 trading days. MarketPing measures each filing's price reaction against it.

When are KRSNAA DIAGNOSTICS LTD's next results?

Financial Results on Mon, 2 Nov. MarketPing alerts you on WhatsApp the moment the filing lands.

Where can I track KRSNAA DIAGNOSTICS LTD's announcements?

Every NSE and BSE filing by KRSNAA DIAGNOSTICS LTD appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.

Figures are as last reported and may lag the latest filing. Not investment advice.